COMMUNIQUÉS West-GlobeNewswire

Lumexa Imaging Advances Growth Strategy by Adding Four New Imaging Centers
12/05/2026
Expansion across the Southeast and Mid-Atlantic includes entry into Pennsylvania through joint venture with University of Pittsburgh Medical Center (UPMC) RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging ( [...]
BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress
12/05/2026
Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and [...]
TELA Bio Reports First Quarter 2026 Financial Results
12/05/2026
MALVERN, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial [...]
Lumexa Imaging Announces First Quarter 2026 Results
12/05/2026
RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, [...]
Interpace Biosciences Announces First Quarter 2026 Financial and Business Results
12/05/2026
Q1 Revenue of $9.0 million Q1 Income from Continuing Operations of $0.8 million Q1 Thyroid volume year-over-year increase of 10% Q1 Thyroid revenue year-over-year increase of 12% PARSIPPANY, NJ, May 12, 2026 (GLOBE [...]
Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026
12/05/2026
INFORMATIONS RÉGLEMENTÉES Nyxoah Publie ses Résultats Financiers et Opérationnels du Premier Trimestre 2026 Le lancement réussi de Genio aux États-Unis génère une croissance trimestrielle séquentielle de 25 % du chiffre [...]
Lifecore Biomedical to Participate at CDMO Live Europe
12/05/2026
CHASKA, Minn., May 12, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR ) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that [...]
Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into [...]
Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
12/05/2026
BERKELEY HEIGHTS, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the [...]
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
Completed spin-off of First Tracks Biotherapeutics, Inc., its former biopharma operations business Now exclusively manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda Announced [...]
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
12/05/2026
Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all [...]
Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
12/05/2026
Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance sheet expected to [...]
Alignment Healthcare Strengthens Leadership Team to Support Long-Term Growth and Shareholder Value Creation
12/05/2026
Founder and CEO John Kao Assumes Additional Role as Chairman of the Board ORANGE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) today announced leadership updates that further [...]
COSCIENS Biopharma Inc. Reports Q1 2026 Results
12/05/2026
TORONTO, ONTARIO, May 12, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“ COSCIENS ” or the “ Company ”) today reported its financial and operating results for the first quarter ended [...]
Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
12/05/2026
C-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to [...]
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
12/05/2026
Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026 Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clinical trial [...]
Nyxoah Reports First Quarter 2026 Financial and Operating Results
12/05/2026
REGULATED INFORMATION Nyxoah Reports First Quarter 2026 Financial and Operating Results Strong Genio launch in the U.S. drove 25% sequential quarterly U.S. revenue growth Continued clarity around HGNS and Genio [...]
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences
12/05/2026
DEER PARK, Ill., May 12, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
12/05/2026
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications Well- [...]

Pages